Thrivent Financial for Lutherans
PCRX icon

Thrivent Financial for Lutherans’s Pacira BioSciences PCRX Stock Holding History

Thrivent Financial for Lutherans’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$656K Sell
25,839
-1,595
-6% -$37.7K ﹤0.01% 2197
2026
Q1 		$620K Sell
27,434
-2,127
-7% -$47.3K ﹤0.01% 2126
2025
Q4 		$765K Sell
29,561
-2,855
-9% -$67.9K ﹤0.01% 2080
2025
Q3 		$835K Sell
32,416
-1,633
-5% -$40.1K ﹤0.01% 1876
2025
Q2 		$814K Buy
34,049
+134
+0.4% +$3.38K ﹤0.01% 1913
2025
Q1 		$843K Sell
33,915
-1,774
-5% -$42.5K ﹤0.01% 1826
2024
Q4 		$672K Sell
35,689
-534
-1% -$9.38K ﹤0.01% 2126
2024
Q3 		$545K Sell
36,223
-2,417
-6% -$41.3K ﹤0.01% 2218
2024
Q2 		$1.1M Sell
38,640
-28,224
-42% -$803K ﹤0.01% 1819
2024
Q1 		$1.95M Sell
66,864
-11,047
-14% -$339K ﹤0.01% 1438
2023
Q4 		$2.63M Sell
77,911
-13,847
-15% -$405K 0.01% 1194
2023
Q3 		$2.81M Buy
91,758
+47,764
+109% +$1.72M 0.01% 1067
2023
Q2 		$1.76M Sell
43,994
-1,476
-3% -$61K ﹤0.01% 1425
2023
Q1 		$1.86M Sell
45,470
-1,593
-3% -$63.4K ﹤0.01% 1347
2022
Q4 		$1.82M Sell
47,063
-306
-0.6% -$14.9K ﹤0.01% 1319
2022
Q3 		$2.52M Buy
47,369
+2,730
+6% +$152K 0.01% 1092
2022
Q2 		$2.6M Buy
44,639
+8,377
+23% +$549K 0.01% 1086
2022
Q1 		$2.77M Buy
36,262
+12
+0% +$800 0.01% 1141
2021
Q4 		$2.18M Buy
36,250
+317
+0.9% +$17.5K ﹤0.01% 1334
2021
Q3 		$2.01M Sell
35,933
-57
-0.2% -$3.29K ﹤0.01% 1349
2021
Q2 		$2.18M Sell
35,990
-42
-0.1% -$2.66K ﹤0.01% 1368
2021
Q1 		$2.52M Buy
36,032
+72
+0.2% +$5.14K 0.01% 1267
2020
Q4 		$2.15M Buy
35,960
+519
+1% +$30.4K 0.01% 1274
2020
Q3 		$2.13M Buy
35,441
+185
+0.5% +$10.7K 0.01% 1121
2020
Q2 		$1.85M Buy
35,256
+282
+0.8% +$11.8K 0.01% 1114
2020
Q1 		$1.17M Buy
34,974
+1,746
+5% +$72.5K ﹤0.01% 1207
2019
Q4 		$1.5M Buy
33,228
+226
+0.7% +$9.6K ﹤0.01% 1197
2019
Q3 		$1.26M Buy
+33,002
New +$1.32M ﹤0.01% 1262
2017
Q2 		– Sell
-38,653
Closed -$1.76M – 2062
2017
Q1 		$1.76M Buy
+38,653
New +$1.67M 0.01% 903

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Thrivent Financial for Lutherans's PCRX Position: Q2 2026 in Review

Thrivent Financial for Lutherans reduced its Pacira BioSciences (PCRX) stake by 5.8% in Q2 2026, selling an estimated $37.7K and leaving 25,839 shares worth $656K. The position accounts for ﹤0.01% of the portfolio, ranked #2197.

Thrivent Financial for Lutherans first reported a position in PCRX in Q1 2017 and has held it in 29 quarters since. The position peaked at $2.81M in Q3 2023. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Thrivent Financial for Lutherans held 25,839 shares of Pacira BioSciences worth $656K as of Q2 2026.
  • Thrivent Financial for Lutherans sold 1,595 Pacira BioSciences shares in Q2 2026, an estimated $37.7K.
  • Pacira BioSciences made up ﹤0.01% of Thrivent Financial for Lutherans's portfolio in Q2 2026, its #2197 holding.
  • Thrivent Financial for Lutherans first reported a position in Pacira BioSciences in Q1 2017 and has held it in 29 quarters since.
  • Thrivent Financial for Lutherans's Pacira BioSciences position peaked at $2.81M in Q3 2023.
  • 253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2026, filed 14 Aug 2026.